JP2008503498A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008503498A5 JP2008503498A5 JP2007516827A JP2007516827A JP2008503498A5 JP 2008503498 A5 JP2008503498 A5 JP 2008503498A5 JP 2007516827 A JP2007516827 A JP 2007516827A JP 2007516827 A JP2007516827 A JP 2007516827A JP 2008503498 A5 JP2008503498 A5 JP 2008503498A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- tuaas
- protein
- antigen
- ssx
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58096904P | 2004-06-17 | 2004-06-17 | |
| PCT/US2005/021836 WO2006002114A2 (en) | 2004-06-17 | 2005-06-17 | Tumor-associated antigen profiles in cancer diagnostics and immunotherapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008503498A JP2008503498A (ja) | 2008-02-07 |
| JP2008503498A5 true JP2008503498A5 (https=) | 2008-08-07 |
Family
ID=35478743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007516827A Pending JP2008503498A (ja) | 2004-06-17 | 2005-06-17 | 癌の診断及び免疫療法における腫瘍関連抗原プロファイル |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1782070B1 (https=) |
| JP (1) | JP2008503498A (https=) |
| AT (1) | ATE480776T1 (https=) |
| AU (1) | AU2005258014B2 (https=) |
| CA (1) | CA2571070A1 (https=) |
| DE (1) | DE602005023488D1 (https=) |
| DK (1) | DK1782070T3 (https=) |
| ES (1) | ES2351995T3 (https=) |
| MX (1) | MXPA06014771A (https=) |
| WO (1) | WO2006002114A2 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2478912B1 (en) | 2003-11-06 | 2016-08-31 | Seattle Genetics, Inc. | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy |
| US20060008468A1 (en) * | 2004-06-17 | 2006-01-12 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in diagnostics for various types of cancers |
| PL1833506T3 (pl) * | 2004-12-29 | 2016-01-29 | Mannkind Corp | Zastosowanie kompozycji zawierających różne antygeny związane z nowotworem jako szczepionek przeciwnowotworowych |
| WO2007140958A2 (en) * | 2006-06-02 | 2007-12-13 | Glaxosmithkline Biologicals S.A. | Method for identifying whether a patient will be responder or not to immunotherapy |
| PE20090943A1 (es) | 2007-07-16 | 2009-08-05 | Genentech Inc | Anticuerpos anti-cd79b e inmunoconjugados |
| EP2176295B1 (en) | 2007-07-16 | 2014-11-19 | Genentech, Inc. | Humanized anti-cd79b antibodies and immunoconjugates and methods of use |
| GB0720118D0 (en) * | 2007-10-15 | 2007-11-28 | Achour Adnane | Modified mhc class 1 binding peptides |
| EP2227558A1 (en) * | 2007-11-30 | 2010-09-15 | GlaxoSmithKline Biologicals SA | Method for classifying cancer patients as responder or non-responder to immunotherapy |
| KR101607346B1 (ko) | 2008-01-31 | 2016-03-29 | 제넨테크, 인크. | 항-ｃｄ７９ｂ 항체 및 면역접합체 및 사용 방법 |
| JP2011512415A (ja) * | 2008-02-20 | 2011-04-21 | アリゾナ バイオメディカル リサーチ コミッション | 癌の治療および予防のための治療用ペプチドの使用 |
| GB0822836D0 (en) * | 2008-12-15 | 2009-01-21 | Oxford Biomedica Ltd | Method |
| US20120100538A1 (en) | 2009-03-24 | 2012-04-26 | Biocept, Inc. | Devices and methods of cell capture and analysis |
| AU2010229924B2 (en) | 2009-03-24 | 2016-07-21 | Plus Therapeutics Inc. | Devices and methods of cell capture and analysis |
| US10066004B2 (en) | 2010-10-12 | 2018-09-04 | Arizona Cancer Therapeutics, Llc | EGFR-based inhibitor peptides for combinatorial inactivation of ERBB1, ERBB2, and ERBB3 |
| CA2814670A1 (en) | 2010-10-12 | 2012-04-19 | Arizona Biomedical Research Commission | Egfr-based peptides |
| BR112013014527A2 (pt) | 2010-12-20 | 2017-03-07 | Genentech Inc | anticorpo isolado, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica, uso do imunoconjugado, método para tratamento de um indivíduo que tem um câncer positivo para mesotelina, para inibição de proliferação de uma célula positiva para mesotelina, para detecção de mesotelina humana em uma amostra biológica e para detectar um câncer positivo para mesotelina |
| US20150044224A1 (en) * | 2012-03-02 | 2015-02-12 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Materials and methods for differential treatment of cancer |
| WO2014074785A1 (en) * | 2012-11-08 | 2014-05-15 | Ludwig Institute For Cancer Research Ltd. | Methods of predicting outcome and treating breast cancer |
| HUE049175T2 (hu) | 2014-09-23 | 2020-09-28 | Hoffmann La Roche | Eljárás anti-CD79b immunkonjugátumok alkalmazására |
| IL260030B2 (en) | 2016-01-08 | 2025-12-01 | Nykode Therapeutics ASA | Therapeutic anticancer neoepitope vaccine |
| US10436771B2 (en) * | 2016-04-05 | 2019-10-08 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and methods for targeted therapy based on single-cell stimulus perturbation response |
| WO2020150513A1 (en) * | 2019-01-17 | 2020-07-23 | Fred Hutchinson Cancer Research Center | Methods to enhance the selectivity and effectiveness of cancer treatments |
| CA3150273A1 (en) * | 2019-08-08 | 2021-02-11 | Cedars-Sinai Medical Center | Method of generating activated t cells for cancer therapy |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4940670A (en) * | 1986-01-24 | 1990-07-10 | Rhodes Buck A | Method for compounding and testing patient specific monoclonal antibodies and monoclonal antibody fragments for in vivo use |
| US6794501B2 (en) | 2001-05-04 | 2004-09-21 | Ludwig Institute For Cancer Research | Colon cancer antigen panel |
| DE10225139A1 (de) * | 2002-05-29 | 2004-02-26 | Immatics Biotechnologies Gmbh | Verfahren zur Identifizierung von immunreaktiven Peptiden |
-
2005
- 2005-06-17 EP EP05766030A patent/EP1782070B1/en not_active Revoked
- 2005-06-17 DE DE602005023488T patent/DE602005023488D1/de not_active Expired - Lifetime
- 2005-06-17 WO PCT/US2005/021836 patent/WO2006002114A2/en not_active Ceased
- 2005-06-17 DK DK05766030.0T patent/DK1782070T3/da active
- 2005-06-17 MX MXPA06014771A patent/MXPA06014771A/es active IP Right Grant
- 2005-06-17 AT AT05766030T patent/ATE480776T1/de not_active IP Right Cessation
- 2005-06-17 JP JP2007516827A patent/JP2008503498A/ja active Pending
- 2005-06-17 CA CA002571070A patent/CA2571070A1/en not_active Abandoned
- 2005-06-17 ES ES05766030T patent/ES2351995T3/es not_active Expired - Lifetime
- 2005-06-17 AU AU2005258014A patent/AU2005258014B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008503498A5 (https=) | ||
| JP2008546687A5 (https=) | ||
| Nagorsen et al. | Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer | |
| Yamada et al. | Next‐generation peptide vaccines for advanced cancer | |
| Del Campo et al. | Immune escape of cancer cells with beta2‐microglobulin loss over the course of metastatic melanoma | |
| Disis | Immune regulation of cancer | |
| Seliger et al. | HER‐2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA‐A2. 1‐restricted cytotoxic T lymphocytes | |
| Suri et al. | Cancer testis antigens: A new paradigm for cancer therapy | |
| Forghanifard et al. | Neoantigen in esophageal squamous cell carcinoma for dendritic cell-based cancer vaccine development | |
| Tang et al. | Strategies used for MUC1 immunotherapy: human clinical studies | |
| Esfandiary et al. | New York esophageal squamous cell carcinoma-1 and cancer immunotherapy | |
| Faramarzi et al. | Melanoma: a prototype of cancer-testis antigen-expressing malignancies | |
| Hale et al. | Cancer vaccines: should we be targeting patients with less aggressive disease? | |
| JP2008526760A5 (https=) | ||
| Jafferji et al. | Adoptive T-cell therapy for solid malignancies | |
| Sasada et al. | Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines | |
| Valilou et al. | Tumor antigens | |
| Weber | Peptide vaccines for cancer | |
| Acres et al. | Targeted immunotherapy designed to treat MUC1-expressing solid tumour | |
| Okada et al. | Immune responses to DNA mismatch repair enzymes hMSH2 and hPMS1 in patients with pancreatic cancer, dermatomyositis and polymyositis | |
| Speetjens et al. | Colorectal cancer vaccines in clinical trials | |
| Pilla et al. | Vaccination: role in metastatic melanoma | |
| Sonpavde et al. | Recent advances in immunotherapy for the treatment of prostate cancer | |
| Madan et al. | PSA-based vaccines for the treatment of prostate cancer | |
| Jäger et al. | The discovery of cancer/testis antigens by autologous typing with T cell clones and the evolution of cancer vaccines |